LNC
VVOS icon

Lincoln National Corp’s Vivos Therapeutics VVOS Stock Holding History

Lincoln National Corp’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-593
Closed -$2.85K – 1133
2023
Q3 		$2.85K Hold
593
– – ﹤0.01% 1020
2023
Q2 		$7.56K Hold
593
– – ﹤0.01% 1014
2023
Q1 		$5.05K Hold
593
– – ﹤0.01% 985
2022
Q4 		$5.96K Buy
+593
New +$8.67K ﹤0.01% 926

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $6.53B AUM 20.48% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Lincoln National Corp's VVOS Position: Q4 2023 in Review

Lincoln National Corp sold out of Vivos Therapeutics (VVOS) in Q4 2023, closing a stake of 593 shares — an estimated $2.85K sold.

Lincoln National Corp first reported a position in VVOS in Q4 2022 and held it in 4 quarters. The position peaked at $7.56K in Q2 2023. 18 funds tracked by Wall St. Rank hold VVOS as of Q4 2023.

  • Lincoln National Corp reported no remaining Vivos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Lincoln National Corp sold 593 Vivos Therapeutics shares in Q4 2023, an estimated $2.85K.
  • Lincoln National Corp first reported a position in Vivos Therapeutics in Q4 2022 and held it in 4 quarters.
  • Lincoln National Corp's Vivos Therapeutics position peaked at $7.56K in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2023.

Based on Lincoln National Corp's 13F filing for Q4 2023, filed 6 Feb 2024.